Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 602

1.

The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.

Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, Mikhailidis DP, Elisaf MS.

J Cardiovasc Pharmacol Ther. 2006 Sep;11(3):211-21.

PMID:
17056835
2.

Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.

Bairaktari ET, Tzallas CS, Tsimihodimos VK, Liberopoulos EN, Miltiadous GA, Elisaf MS.

J Cardiovasc Risk. 1999 Apr;6(2):113-6.

PMID:
10353071
3.

Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.

Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M; LCP-AtorFen Investigators.

Clin Ther. 2009 Dec;31(12):2824-38. doi: 10.1016/j.clinthera.2009.12.007.

PMID:
20110022
5.

Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia.

Melenovsky V, Malik J, Wichterle D, Simek J, Pisarikova A, Skrha J, Poledne R, Stavek P, Ceska R.

Am Heart J. 2002 Oct;144(4):E6.

PMID:
12360175
6.

One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.

Avellone G, Di Garbo V, Abruzzese G, Campisi D, De Simone R, Raneli G, Licata G.

Int Angiol. 2006 Mar;25(1):26-34.

7.

Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.

Sharma R, Mahajan M, Singh B, Bal BS, Kant R.

J Indian Med Assoc. 2006 Sep;104(9):492-4, 496, 498.

PMID:
17388006
8.
9.

Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment.

García-Otín AL, Civeira F, Aristegui R, Díaz C, Recalde D, Sol JM, Masramon X, Hernández G, Pocoví M; ATOMIX Study Group. Atorvastatin in Mixed dyslipidemia.

Eur J Clin Invest. 2002 Jun;32(6):421-8.

PMID:
12059987
10.

Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.

Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV.

Metabolism. 2000 Feb;49(2):167-77.

PMID:
10690940
13.

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.

Freed MI, Ratner R, Marcovina SM, Kreider MM, Biswas N, Cohen BR, Brunzell JD; Rosiglitazone Study 108 investigators.

Am J Cardiol. 2002 Nov 1;90(9):947-52.

PMID:
12398960
14.

Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.

Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, Fraioli A, Mastrantoni M, Maddaloni M, Letizia C.

Metabolism. 2007 Nov;56(11):1534-41.

PMID:
17950105
15.

Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.

Steinmetz A, Schwartz T, Hehnke U, Kaffarnik H.

J Cardiovasc Pharmacol. 1996 Apr;27(4):563-70.

PMID:
8847874
16.

Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.

Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P, Hoffmann MM, Baumstark MW, Wieland H, März W.

Exp Clin Endocrinol Diabetes. 2004 May;112(5):241-7.

PMID:
15146369
17.

Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.

Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagné C, Couture P.

Metabolism. 2008 Mar;57(3):380-6. doi: 10.1016/j.metabol.2007.10.014.

PMID:
18249211
18.
19.

Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.

Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, Couture P.

Metabolism. 2008 Feb;57(2):246-54. doi: 10.1016/j.metabol.2007.09.008.

PMID:
18191056
20.

Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.

Ooi TC, Heinonen T, Alaupovic P, Davignon J, Leiter L, Lupien PJ, Sniderman AD, Tan MH, Tremblay G, Sorisky A, Shurzinske L, Black DM.

Arterioscler Thromb Vasc Biol. 1997 Sep;17(9):1793-9.

PMID:
9327779

Supplemental Content

Support Center